Gemcitabine Injection is a medicine that is used for the treatment of Ovarian Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer and other conditions.
Gemcitabine Injection contains Gemcitabine Hydrochloride as an active ingredient.
Gemcitabine Injection works by destroying the cells undergoing deoxyribonucleic acid synthesis.
Detailed information related to Gemcitabine Injection's uses, composition, dosage, side effects and reviews is listed below.
Gemcitabine Injection is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:
· Ovarian Cancer
· Breast Cancer
· Non-Small Cell Lung Cancer
· Pancreatic Cancer
Gemcitabine Injection improves the patient's condition by performing the following functions:
· Destroying the cells undergoing deoxyribonucleic acid synthesis.
Gemcitabine Injection is composed of the following active ingredients (salts)
· Gemcitabine Hydrochloride (1000Mg/50Ml)
Please note that this medicine may be available in various strengths for each active ingredient listed above.
The following is a list of possible side-effects that may occur from all constituting ingredients of Gemcitabine Injection. This is not a comprehensive list. These side-effects are possible, but do not always occur. Some of the side-effects may be rare but serious. Consult your doctor if you observe any of the following side-effects, especially if they do not go away.
· Increased Alkaline Phosphatase
Before using this drug, inform your doctor about your current list of medications, over the counter products (e.g. vitamins, herbal supplements, etc.), allergies, pre-existing diseases, and current health conditions (e.g. pregnancy, upcoming surgery, etc.). Some health conditions may make you more susceptible to the side-effects of the drug. Take as directed by your doctor or follow the direction printed on the product insert. Dosage is based on your condition. Tell your doctor if your condition persists or worsens. Important counseling points are listed below.
· avoid the use of radiation therapy
· quit the therapy if capillary leak syndrome occurs
· quit the therapy if the posterior reversible encephalopathy syndrome occurs
The most common markets for this product include the following countries. Please inquire with us if your country or region is not listed:
Asia: Afghanistan, Israel, Jordan, Pakistan, Russia, Saudi Arabia, Singapore, Syria, Philippines, Turkey, Turkmenistan, Uzbekistan, Yemen, Vietnam, Indonesia, Malaysia, Iran, Tajikistan, etc.
Africa: South Africa, Uganda, Nigeria, Ghana, Kenya, Mauritius, Botswana, Egypt, Ethiopia, Libya, Sudan, Congo, Gambia, Ivory Coast , etc.
North & South America: USA, Canada, Panama, Trinidad and Tobago, Costa Rica, Puerto Rico, Dominican Republic, Argentina, Guatemala, Guyana, Peru, Bolivia, Venezuela , Brazil, Bahamas, Ecuador, etc .
Europe: Austria , Azerbaijan, Belarus, Belgium, Cyprus, Czech Republic, Denmark, France, Georgia, Germany, Hungary, Ireland, Iceland, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Ukraine, United Kingdom (UK) , Latvia, etc.
OCEANIA: Australia, New Zealand, Fiji, etc.
Sorafenib Tosylate Tablets
Vincristine Sulphate Injection
Tamoxifen Citrate Tablets
Estramustine Phosphate Capsules
Sunitinib Malate Capsules
Abiraterone Acetate Tablets
Zoledronic Acid Injection
Vinblastine Sulphate Injection
Erythropoietin Prefilled Syringe Injection